Breast Cancer

FDA grants olaparib priority review in BRCA-mutated HER2-negative high-risk early breast cancer

December 01, 2021

Olaparib, which was granted priority review by the FDA, has been shown to improve invasive disease-free survival for patients with BRCA-mutated HER2-negative high-risk early breast cancer.

Racial disparities in surgical management of breast cancer among Native American and Native Alaskan patients

November 12, 2021

Findings from a study indicated that non-Hispanic American Indian and Alaskan Native patients with breast cancer were more likely to undergo a mastectomy compared with non-Hispanic White patients.

Same mutations linked to breast cancer risk found in black, white women

November 08, 2021

A recently published study evaluated nearly 30,000 patients and found about 5% of Black and White women have the same genetic mutations that are associated with an increased risk of breast cancer.

Lack of health insurance directly reduces cancer screening rates, most recent and long-term

November 08, 2021

Disparities across the globe continue to surface as we approach year 2 of the COVID-19 pandemic, especially in health care. As one considers its implications, a research team from the American Cancer Society investigated its potential impact on early cancer detection.

New study shows racial disparities in genetic testing referrals for women

November 05, 2021

A recent study suggests that unconscious or implicit bias may exist when it comes to physicians referring African American patients with breast cancer for genetic counseling and testing.

Breast cancer paradigm moves toward less morbid treatments with improved risk assessment and imaging strategies

November 03, 2021

Paul Lawrence Baron, MD, discussed best practices for determining a patient’s risk of developing breast cancer, the significance of targeting HER2 in patients with early-stage and metastatic disease, and remaining questions with radiation therapy in the field.

Dynamic treatment for early-stage triple-negative breast cancer

November 02, 2021

Standard chemotherapy has historically been the mainstay of treatment for patients with diagnoses of early-stage TNBC, but there remains an unmet need to identify novel therapies that improve outcomes and, equally important, to discern which patients may benefit from a given treatment.